{"id":66680,"date":"2026-05-29T13:30:43","date_gmt":"2026-05-29T05:30:43","guid":{"rendered":"https:\/\/flcube.com\/?p=66680"},"modified":"2026-05-29T13:30:45","modified_gmt":"2026-05-29T05:30:45","slug":"jj-secures-fda-approval-for-tremfya-label-expansion-to-include-structural-joint-damage-inhibition-in-psoriatic-arthritis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66680","title":{"rendered":"J&J Secures FDA Approval for TREMFYA Label Expansion to Include Structural Joint Damage Inhibition in Psoriatic Arthritis"},"content":{"rendered":"\n

Johnson & Johnson<\/strong> (J&J, NYSE: JNJ<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved a supplemental Biologics License Application (sBLA)<\/strong> to update the label for TREMFYA\u00ae (guselkumab)<\/strong>, an IL-23 antibody<\/strong>, to include evidence of inhibition of structural joint damage progression<\/strong> in adults with active psoriatic arthritis (PsA)<\/strong>.<\/p>\n\n\n\n

Regulatory Approval Details<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>FDA (United States)<\/td><\/tr>
Approval Type<\/strong><\/td>Supplemental Biologics License Application (sBLA)<\/td><\/tr>
Product<\/strong><\/td>TREMFYA\u00ae (guselkumab) \u2013 IL-23 antibody<\/td><\/tr>
Indication<\/strong><\/td>Inhibition of structural joint damage progression in active psoriatic arthritis<\/td><\/tr>
Approval Date<\/strong><\/td>28 May 2026<\/td><\/tr>
Supporting Data<\/strong><\/td>24-week results from Phase 3b APEX study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 Phase 3b APEX Study<\/h2>\n\n\n\n
Endpoint<\/th>Result (TREMFYA)<\/th>Comparator (Placebo)<\/th>Significance<\/th><\/tr><\/thead>
Primary Endpoint<\/strong><\/td>Met ACR20 response<\/td>Lower response rate<\/td>Statistically significant improvement in joint symptoms<\/td><\/tr>
Major Secondary Endpoint<\/strong><\/td>Reduced structural damage progression (vdH-S score)<\/td>Greater progression<\/td>Demonstrated inhibition of radiographic joint damage<\/td><\/tr>
Crossover Analysis<\/strong><\/td>57% reduction in radiographic progression (Week 24-48)<\/td>Initial placebo group<\/td>Benefit observed even after disease progression<\/td><\/tr>
Safety Profile<\/strong><\/td>Consistent with established profile<\/td>\u2013<\/td>No new safety signals identified<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The APEX study specifically evaluated bio-na\u00efve patients with active psoriatic arthritis, providing robust evidence for TREMFYA’s dual benefit on both symptomatic relief and structural preservation.<\/p>\n\n\n\n

Market Impact & Strategic Implications<\/h2>\n\n\n\n